PREVENTION OF OVARIAN CANCER BY ADMINISTRATION OF PRODUCTS THAT INDUCE BIOLOGICAL EFFECTS IN THE OVARIAN EPITHELIUM
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to compositions and methods for preventing the development of epithelial ovarian cancer by administering compounds in an amount capable of regulating TGF-β expression in the ovarian epithelium and/or capable of optimally altering expression of other surrogate biomarkers identified by microarray technology. HRT and OCP regimens comprising such compositions and methods are disclosed.
96 Citations
58 Claims
-
1-33. -33. (canceled)
- 34. A composition comprising a phytoestrogen compound and a progestin.
- 43. A composition comprising an isoflavone and a progestin.
- 48. A composition comprising genistein and a progestin.
- 53. A composition comprising an isoflavone compound and a progestin, wherein the dosage of said isoflavone compound is at least 20 mg and said isoflavone compound is selected from the group consisting of genistein, forms of genistin, and combinations thereof.
- 56. A composition comprising an isoflavone compound and a progestin, wherein the dosage of said isoflavone compound is at least 20 mg and said isoflavone compound is selected from the group consisting of daidzein, forms of daidzin, and combinations thereof.
Specification